Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

Inventors

Wang, Guoqiang • Shen, Ruichao • Granger, Brett • He, Jing • Xing, Xuechao • He, Yong • Long, Jiang • Ma, Jun • Wang, Bin • Or, Yat Sun

Assignees

Enanta Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12459923-B2

Patent

Publication Date

2025-11-04

Expiration Date


Abstract

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Core Innovation

The disclosed subject matter encompasses substituted pyrazole-benzamide and heteroaryl carboxamide compounds represented by Formula I, or a pharmaceutically acceptable salt or ester thereof, functioning as ASK-1 inhibitors. In the claimed Formula I genus, R1 is selected from trifluoromethyl, isopropyl, cyclopropyl, or t-butyl; X is N or C-R3; R3 is fluorine or methoxy; and R4 is methyl, difluoromethyl, or trifluoromethyl. The disclosure also encompasses Formula II through IV subfamilies, depicted compounds, and pharmaceutical compositions.

Exemplified embodiments incorporate pyridine, thiazole, pyrazole, imidazole, tetrazolyl-pyridyl, and fluorinated aryl groups, including analogs with cyclopropyl, tert-butyl, or hydroxypropyl-substituted tetrazole groups. Because background, summary, and abstract sections are omitted from the provided text, the specific technical problem addressed is not explicitly described. Disclosed embodiments report ASK-1 kinase inhibition, providing screening results showing activity across nanomolar ranges for compounds within the claimed Formula I genus.

Claims Coverage

The claims identify one independent claim, presenting one inventive feature directed to a defined chemical genus.

Formula I compound genus with specified substituents

A compound represented by Formula I, or a pharmaceutically acceptable salt or ester thereof, wherein R1 is selected from trifluoromethyl, isopropyl, cyclopropyl, or t-butyl; X is N or C-R3; R3 is fluorine or methoxy; and R4 is methyl, difluoromethyl, or trifluoromethyl.

The independent claim defines the Formula I compound genus and its pharmaceutically acceptable salts or esters, while dependent claims further specify formula subfamilies, depicted compounds, pharmaceutical compositions with a carrier or excipient, and methods of treatment for ASK-1-mediated conditions.

Stated Advantages

The reported results support potent ASK1-inhibitory activity of compounds in the claimed Formula I genus.

Documented Applications

Pharmaceutical compositions comprising a claimed Formula I compound and a pharmaceutically acceptable carrier or excipient.

Prevention or treatment of ASK-1-mediated diseases or conditions, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatic steatosis, diabetic nephropathy, myocardial ischemia, glomerulonephritis, and other renal, cardiovascular, inflammatory, and metabolic conditions.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.